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Abstract
Background: Recently, microRNA-21 (miR-21) has been reported to be associated with prognosis of pancreatic
ductal adenocarcinoma (PDAC). The present studies aimed to evaluate the prognostic value of miR-21 for PDAC
with meta-analysis.
Methods: A systematic search in the PubMed and other databases was conducted to identify eligible studies. The
pooled hazard ratios (HRs) with 95 % confidence interval (CI) were calculated. The meta-analysis was conducted
using the STATA 12.0 software.
Results: A total of 12 articles (13 studies) which included 963 cases were selected for the meta-analysis. Elevated
miR-21 expression was significantly predictive of poor overall survival (HR = 2.05, 95 % CI 1.71–2.46, P < 0.001). In the
subgroup analyses, similar results were observed in Asian (HR = 2.09, 95 % CI 1.62–2.71, P < 0.001) and Caucasian
(HR = 2.36, 95 % CI 1.53–3.65, P < 0.001); in tissue sample (HR = 2.14, 95 % CI 1.73–2.65, P < 0.001) and serum sample
(HR = 1.84, 95 % CI 1.30–2.60, P = 0.001); with quantitative real-time polymerase chain reaction assay method (HR = 2.31,
95 % CI 1.86–2.86, P < 0.001); and in patients receiving adjuvant chemotherapy (HR = 2.37, 95 % CI 1.88–3.00, P < 0.001).
The association between miR-21 expression level and lymph node metastasis was statistically significant (OR = 1.45,
95 % CI 1.02–2.06, P = 0.038). However, no significant relationship between miR-21 expression level and sex or vascular
invasion or neural infiltration was observed (P > 0.05).
Conclusions: Our meta-analysis indicated that elevated miR-21 expression level can predict poor prognosis in patients
with PDAC.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most aggressive malignancies and the fourth cause of
cancer-related death [1]. Despite the advancement in
medical and surgical managements, the outcome of
PDAC remains disappointing. Only 15 % of patients can
undergo radically surgical resection [2] and approxi-
mately 6 % of patients can survive for 5 years following
diagnosis [1]. The poor prognosis of PDAC primarilyat-
tributes to the facts including late clinical manifestation,
aggressive local invasion, high metastatic potential, and
chemotherapy or radiotherapy resistance. These chal-
lenges motivate researchers to seek better approaches
for PDAC, including finding out new biomarkers which
can identify different phenotypes with differences in
clinical feature and prognosis.
MicroRNAs are a class of small non-coding RNA,
approximately 20 nucleotides in length [3]. By base
pairing with the 3′-untranslated region (UTR) of target
messenger RNAs, microRNAs act as endogenous regula-
tors of protein-coding genes at transcriptional or post-
transcriptional level [3, 4]. Thus, microRNAs (miRNAs)
are involved in various biological processes, such as
differentiation, proliferation, cell cycle regulation, and
metabolism [5, 6]. More importantly, mounting evi-
dences suggest that microRNAs are involved in cancer
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development and progression including activation of on-
cogenes and inactivation of tumor suppressor genes [7, 8].
MiR-21 is the most frequently observed cancer-related
microRNA. Previous studies have observed that miR-21
dysregulates in many cancers and acts as a key factor
mediating the growth, development, and progression of
tumors [9–11], which is expected to be a novel predictor
and target. However, evidence for the prognostic role of
miR-21 expression in PDAC was still lacking. Thus, we
conduct this meta-analysis to evaluate the prognostic
value of miR-21 for PDAC.
Methods
Search strategy
A systematic search in the PubMed, ISI Web of Science,
and EMBASE databases was performed to identify studies
published before February 2016. The detailed keywords
for the PubMed searches were as follows:
Fig. 1 The PRISMA flowchart of literature review
Table 1 The characteristics of the pooled studies




Dillhoff 2008 USA Caucasian 80 NR OS KM OS, 4.08 (1.98, 8.38), P = 0.037 NR
Giovannetti a 2010 Italy Caucasian 28 I–III OS, DFS U OS, 3.1 (1.4–7.3), P = 0.008 Y
DFS, 4.4 (1.8–10.7), P = 0.001
Giovannetti b 2010 Italy Caucasian 31 IV OS, PFS U OS, 3.1 (1.4–7.1), P = 0.01 Y
PFS, 2.4 (1.1–5.3), P = 0.03
Hwang 2010 Korea Asian 82 II–IV OS, DFS M OS, 2.26 (1.34, 3.80), P = 0.002 Y
DFS, 2.793 (1.466–5.319), P = 0.002
Jamieson 2012 UK Caucasian 48 II–IV OS M OS, 3.22 (1.21–8.58), P = 0.019 Y
Liu 2012 China Asian 38 I–IV OS KM OS, 2.89 (1.22–6.81), P = 0.02 NR
Nagao 2012 Japan Asian 65 I–IV OS U OS, 2.32 (1.19–4.52), P = 0.045 NR
Wang 2013 China Asian 177 III–IV OS M OS, 1.71 (1.15–2.54), P = 0.008 Y
Kadera 2013 USA Caucasian 145 I–IV OS U OS, 1.1 (0.7–1.6), P = 0.7 NR
Papaconstantinou 2013 Greece Caucasian 88 I–IV OS M OS, 1.72 (1.25–12.3), P = 0.019 NR
Ma 2013 China Asian 78 I–IV OS M OS, 2.60 (1.15–5.87), P = 0.021 NR
Dhayat 2015 Germany Caucasian 91 II OS, RFS M OS, 3.06 (1.37–6.85), P = 0.0064 Y
RFS, 2.25 (1.06–4.77), P = 0.0338
Khan 2015 UK Caucasian 12 IV OS, PFS KM OS, 1.46 (0.41–5.21), P = 0.564 Y
PFS, 4.7 (1.1–19.7), P = 0.032
OS overall survival, DFS disease-free survival, RFS relapse-free survival, PFS progression-free survival, KM Kaplan–Meier analysis, U univariate analysis, M multivariate
analysis, Y yes, NR not reported










(10)#1 OR #2 OR #3
(11)#4 OR #5 OR #6
(12)#7 OR #8 OR #9
(13)#10 AND #11 AND #12
All of the studies which fulfilled the following criteria
were included in the meta-analysis: (1) studied PADC
based on histopathological confirmation; (2) expression
of miR-21 was measured; (3) the association between
expression of miR-21 level and survival outcome was
studied. Studies were excluded based on the following
criteria: (a) reviews, letters or laboratory studies, un-
published studies with only the abstracts presented at
Table 2 The technical details in detection of miR-21 expression
Study Sample size Sample Sample technique Method Endogenous control Cutoff
Dillhoff 80 FFPE MDS ISH RNU6 Score > 1
Giovannetti a 28 Tissue MDS RT-PCR RNU43 Median
Giovannetti b 31 Tissue MDS RT-PCR RNU44 Median
Hwang 82 FFPE MDS RT-PCR RNU66 or RNU43 Median
Jamieson 48 FT NR RT-PCR RNU6 Median
Liu 38 Serum RT-PCR NR NR
Nagao 65 FFPE NR RT-PCR RNU6 Mean
Wang 177 Serum RT-PCR RNU7 Median
Kadera 145 FFPE NR ISH RNU6 Median
Papaconstantinou 88 FFPE NR RT-PCR RNU6 Mean
Ma 78 FT NR RT-PCR RNU6 ≥2-fold change
Dhayat 91 FFPE NR RT-PCR NR Mean
Khan 12 Serum ISH NR Median
FFPE formalin-fixed paraffin-embedded, FT frozen tissue, MD microdissected sample, ISH in situ hybridization, qRT-PCR quantitative real-time polymerase chain reaction
assay, NR not reported
Fig. 2 The relationship between elevated miR-21 level and OS
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national and international meetings; (b) studies had
overlapping or duplicate data; (c) absence of necessary
information to calculate HR. All references of retrieved
articles were manually selected to identify all the poten-
tial studies. The language of the articles was limited to
English. A flow diagram of the study selection process
is presented in Fig. 1.
Data extraction
Two reviewers (FT and KWJ) independently extracted
the data following the guidelines of a critical review
checklist of the Dutch Cochrane Centre proposed by
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) [12] and decided upon the controversial issues
through discussion. For disagreements, a consensus was
reached by a third investigator (WW). The following
information was extracted from each study: author, pub-
lished year, country or area, ethnicity, sample size, sample
type, TNM stage, detection method, cutoff value, follow-
ups, adjuvant therapy, HRs with 95 % confidence intervals
(CIs), and P value of miR-21 for overall survival (OS). If
not available, data were extracted using the method
described by Tierney et al. [13].
Statistical analysis
Pooled hazard ratio (HR) of miR-21 expression for OS was
calculated. The heterogeneity was checked using I2 statistic
described by Higgins [14]. A P < 0.05 or I2 > 50 % for Q test
suggested significant heterogeneity among studies. If high
heterogeneity exists among studies, pooled effect was calcu-
lated using the random-effects model (DerSimonian–Laird
method) [15], Otherwise, the fixed-effects model (Mantel–
Fig. 3 Subgroup analyses of relationship between elevated miR-21 level and OS by ethnicity. a Asian. b Caucasian
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Haenszel method) was used [16]. Publication bias was
assessed using the funnel plot. Subgroup analysis of PADC
patients with elevated miR-21 expression were examined
with respect to gender (male vs. female), lymph node me-
tastasis (positive vs. negative), vascular invasion (positive vs.
negative), and neural infiltration (positive vs. negative). Data
analyses were performed using STATA software version
12.0 (STATA Corporation, College Station, TX, USA).
P < 0.05 was considered statistically significant.
Results
Summary of included study characteristics
A total of 206 published articles were initially retrieved in
the databases of PubMed, EMBASE, and Web of Science.
After abstract review, 189 articles were removed which left
17 articles for full-text evaluation. Finally, 12 articles (13
studies) remained which excluded 5 articles following full-
text evaluation [17–28], Fig. 1. The main characteristics
and results of the eligible studies are summarized in
Table 1. These studies investigated a total of 963 cases
from USA, China, Italy, UK, Korea, Japan, Greece, and
Germany. MiR-21 expression was detected by either quan-
titative real-time polymerase chain reaction assay (qRT-
PCR) or in situ hybridization (ISH) with 6 in FFPE, 2 in
cancerous tissue, 2 in frozen tissue, and 3 in serum. The
cutoff values of miR-21 varied in each study. Median and
mean values were extracted from 9 studies; 2-fold values
or score > 2 or score > 1 were considered in the remaining
4 studies and Liu et al. did not report the cutoff value [22].
The technical details in the detection of miR-21 expres-
sion are summarized in Table 2.
Correlation between miR-21 expression and survival outcome
Elevated miR-21 expression was significantly predictive of
poor OS (HR= 2.05, 95 % CI 1.71–2.46, P < 0.001), Fig. 2.
In the subgroup analyses by ethnicity, no matter the cases
Fig. 4 Subgroup analyses of relationship between elevated miR-21 level and OS by sample type. a Tissue. b Serum
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were Asian or Caucasian, the high-level miR-21 expression
was still a significantly poor predictor for OS (Asian, HR =
2.09, 95 % CI 1.62–2.71, P < 0.001; Caucasian, HR = 2.36,
95 % CI 1.53–3.65, P < 0.001), Fig. 3. We also observed that
the high-level miR-21 expression was associated with
poor OS both in tissue sample (HR = 2.14, 95 % CI
1.73–2.65, P < 0.001) and serum sample (HR = 1.84,
95 % CI 1.30–2.60, P = 0.001), Fig. 4. Further analyses
of studies revealed that the high-level miR-21 expres-
sion detected by the qRT-PCR method predicted poor
OS (HR = 2.31, 95 % CI 1.86–2.86, P < 0.001), while
similar result did not arise in high-level miR-21 expres-
sion detected by the ISH method (HR = 1.86, 95 % CI
0.73–4.74, P = 0.191), Fig. 5. In patients receiving adju-
vant chemotherapy, high expression of miR-21 is also
associated with poor prognosis (HR = 2.37, 95 % CI
1.88–3.00, P < 0.001), Fig. 6.
Correlation between miR-21 expression and clinical
characteristics
There were 4 studies that reported correlations between
miR-21 expression and some clinical characteristics (sex,
lymph node metastasis, vascular invasion, and neural
infiltration). The association between miR-21 expression
level and lymph node metastasis was statistically signifi-
cant (OR = 1.45, 95 % CI 1.02–2.06, P = 0.038). However,
no significant relationship between miR-21 expression
level and sex or vascular invasion or neural infiltration
was observed, Table 3.
Publication bias and sensitivity analysis
The publication bias of the pooled studies was evaluated
by funnel plots. Visual inspection of the funnel plots was
almost symmetric in studies reported OS, Fig. 7. Sensi-
tivity analysis was performed by exclusion of the highest
Fig. 5 Subgroup analyses of relationship between elevated miR-21 level and OS by detection method. a qRT-PCR. b ISH
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weighted study and there was no individual study dom-
inantly influenced overall HR.
Discussion
Recently, miR-21 has gain wide attentions in cancer re-
search for its crucial role in gene regulation and cancer
development. The potential role of miR-21 as a novel
diagnostic or prognostic biomarker has proved by accu-
mulated evidence in various types of cancer, such as
colon cancer, gastric cancer, breast cancer, and lung
cancer [29–32]. Regarding PDAC, although the potential
diagnostic effect of miR-21 had already been reported
[22, 33, 34], the prognostic role is still contingent. In
addition, the relation between the expression of miR-21
and patients’ clinical characteristics still needs to be defined.
In this meta-analysis, the pooled HR from 963 patients
in 13 studies for OS was 2.05 (95 % CI 1.71 to 2.46, P <
0.01), which was considered strongly predictive [35]. Our
present meta-analysis found strongly predictive value of
miR-21 both in Asian and Caucasian patients; thus, we as-
sume that it may be applied as a general prognostic marker
regardless of ethnicity. An ideal prognostic biomarker
should be convenient, sensitive, and credible. The majority
of pooled studies detected the miR-21 expression in the
tissue with qRT-PCR method. Elevated expression of miR-
21 in the serum sample also predicted poor prognosis as
tissue sample, which may be favored in the clinical man-
agement of PDAC. Conversely, in the subgroup analysis of
ISH method, elevated expression of miR-21 did not imply
poor outcomes. This result should be elaborated causing
limited pooled studies using ISH method with a different
cutoff value. Therefore, further studies with consistent
normalization are warranted. Though we did not report
the pooled relationship of miR-21 with disease-free sur-
vival, relapse-free survival, and progression-free survival
due to limited studies for analysis, several studies demon-
strated the significant prediction of miR-21 on these prog-
nostic outcomes [18, 19, 27, 28]. Moreover, the patients’
clinical characteristics, including male gender, positive
vascular infiltration, and positive neural infiltration showed
no correlation with high miR-21 expression, but positive
lymph node metastasis showed significant correlations.
This important feature was consistent with several other
malignancies [36, 37]. Kadera et al. reported that pancreatic
Fig. 6 The relationship between elevated miR-21 level and OS in patients with chemotherapy
Table 3 Correlation between miR-21 expression and clinical characteristics
Variables Number of studies Model OR(95 % CI), P value Heterogeneity (I2, P-value)
Gender (male vs. female) 4 Fixed 1.05(0.75–1.47), 0.78 0.0 %, 1.00
Lymph node metastasis (positive vs. negative) 4 Fixed 1.45(1.02–2.06),0.04 0.0 %, 0.70
Vascular infiltration (yes vs. no) 3 Fixed 0.91(0.47–1.76),0.78 0.0 %,0.79
Neural infiltration (yes vs. no) 3 Fixed 1.30(0.80–2.10),0.29 0.0 %,0.67
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cancer cells induce the fibroblasts with high expression of
miR-21 and increase the invasive potential as manifested
by lymph node metastasis [21].
As potential mechanisms of enhanced PDAC invasion,
miR-21 has been identified to target on the phosphatase
and tensin homolog (PTEN). The PTEN gene in humans
generally acts as a tumor suppressor gene through the ac-
tions of its phosphatase protein product [38], which plays a
critical role in cell cycle arrest, cell migration, cell spread-
ing, and cell invasions. Aberrant expression of PTEN was
associated with the development and progression of mul-
tiple tumors [39, 40]. Meng et al. found that inhibition of
miR-21 in cultured HCC cells increased the expression of
PTEN [41]. Giovannetti et al. reported that transfection
with pre-miR-21 resulted in the reduction of PTEN ex-
pression [18], suggesting that PTEN was a direct target
of miR-21. The reversion-inducing-cysteine-rich protein
with Kazal motifs (RECK) is another potential target gene
of miR-21 identified recently. RECK functions as a metas-
tasis suppressor by membrane-bound inhibiting MMPs,
which play an important role in extracellular matrix re-
modeling during tumor progression [42, 43]. Zhao et al.
reported that miR-21 modulated the RECK expression
through directly binding to RECK 3′-UTR [44]. Down-
regulation of RECK expression was observed in tumors
including PDAC when the expression of miR-21 is ele-
vated [45, 46].
Several clinical trials have approved that adjuvant
chemotherapy can effectively improve the outcome of
PDAC [47, 48]. The gemcitabine or 5-fluorouracil-based
chemotherapy was considered as the most effective
regimen till now, while the response to the adjuvant
chemotherapy remains unsatisfactory. The dense fibrotic
bulk of PDAC appears to impede the delivery of chemo-
therapeutic drugs to cancer cells. More importantly,
miR-21 expression is likely to be correlated with che-
moresistance as growing evidence suggests that aberrant
miR-21 expression strongly cripples the response to the
chemotherapy [49–51]. The present meta-analysis re-
vealed that elevated expression of miR-21 was associated
with shorter OS in patients with chemotherapy as well.
Higher expression of miR-21 was detected in PDAC cells
with the higher 50 % inhibitory concentration values of
gemcitabine or 5-fluorouracil [18, 19]. Meanwhile, anti-
sense inhibition of miR-21 induced the reduction of can-
cer cell proliferation, invasion, and chemoresistance
against gemcitabine and 5-fluorouracil [52].
Apoptotic evasion is considered to be one of the main
causes of chemoresistance. Previous studies have revealed
that overexpression of miR-21 can down-regulate PTEN
expression and consequently activate the PI3K/Akt signal-
ing pathway, while anti-miR-21 strategy strongly reduced
phospho-AKT levels and enhanced apoptosis when used
in combination with gemcitabine [18]. Furthermore, Toste
et al. identified an inverse correlation between miR-21 and
p85α [53], a major negative regulatory subunit of PI3K/
Akt signaling [54], which was likely a potential mechanism
for the known relationship between miR-21 expression
and PI3K/Akt signaling. Beyond this, Wang et al. reported
that miR-21 directly regulates the FasL/Fas pathway by
binding the 3′-UTR region of the FasL messenger RNA
(mRNA). Additionally, ectopic expression of FasL
Fig. 7 Funnel plot for publication bias analysis based on OS
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significantly abrogated the miR-21-induced chemoresis-
tance [26]. These evidences may also partially explain that
high expression of miR-21 predicts poor prognosis.
Although miR-21 holds a great promise as a novel prog-
nostic biomarker for PADC, several limitations need to be
addressed in practical application. Firstly, statistical het-
erogeneity among pooled studies, which may be derived
from different ethnicities (Caucasian vs. Asian), sample
types (tissue vs. serum), treatment (without chemotherapy
vs. with gemcitabine or 5-fluorouracil), different detection
methods (qRT-PCR vs. ISH), decreased the plausibility of
the results. Secondly, only studies published in English
were pooled in this meta-analysis which may omit some
valuable articles on this issue. Thirdly, miR-21 as a novel
prognostic marker of PDAC just looms in recent years,
and still limited research work was done. So, the study size
obtained in this meta-analysis was relatively small.
Conclusions
In conclusion, the current meta-analysis demonstrated that
miR-21 might serve as a potential prognostic marker of
PDAC. Due to some limitations of this study, more com-
plementary researches are awaited to validate our results.
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